van Battum P L, van de Vrie W, Metselaar H J, Verstappen V M, Zondervan P E, de Man R A
St. Maartens Gasthuis, afd. Inwendige Geneeskunde, Venlo.
Ned Tijdschr Geneeskd. 2000 Oct 7;144(41):1964-7.
A 50-year-old man developed acute liver failure 7 months after nefazodone treatment was initiated. There was no evidence of any aetiology apart from the exposure to the antidepressant drug nefazodone, while the results of repeated histological examinations of the liver were compatible with serious progressive drug-induced hepatitis. This diagnosis was initially disregarded because in the literature no patients with nefazodone-induced hepatitis were reported. However, the drug had only recently been introduced, which meant that relatively infrequent adverse drug reactions might not have been published. Further analyses of databases of the marketing pharmaceutical industry and of the World Health Organization revealed more cases of liver toxicity ascribed to nefazodone, which showed that liver failure may indeed be associated with nefazodone use. Consequently, prescribing doctors have been warned by the pharmaceutical company about this possible adverse drug reaction.
一名50岁男性在开始使用奈法唑酮治疗7个月后出现急性肝衰竭。除了接触抗抑郁药奈法唑酮外,没有任何病因的证据,而肝脏反复组织学检查结果与严重的进行性药物性肝炎相符。该诊断最初被忽视,因为文献中未报道有奈法唑酮引起肝炎的患者。然而,这种药物最近才被引入,这意味着相对罕见的药物不良反应可能尚未发表。对制药行业和世界卫生组织数据库的进一步分析发现了更多归因于奈法唑酮的肝毒性病例,这表明肝衰竭确实可能与使用奈法唑酮有关。因此,制药公司已就此可能的药物不良反应向开处方的医生发出警告。